Association for Accessible Medicines

06/15/2026

A Call for PBM Reform is A Call for Lower Drug Prices for Americans

Prescription medicine pricing and reimbursement processes must be governed by transparency, accountability, and healthy competition. To realize the full savings potential of generic and biosimilar medicines and safeguard health budgets, policymakers should take decisive steps to reform PBM practices NOW!

Learn more: https://accessiblemeds.org/advocacy/pbm-reform/

06/09/2026

PBMs DELAY PATIENT SAVINGS! First generics, or medicines approved by FDA as the first competitor to the brand drug, often face challenges in market adoption. Slower adoption for first generics is driven in part by slower coverage decisions of PBMs and health plans. These entities benefit from rebates on high-priced brand drugs, even though patients would save through lower-cost generics and biosimilars. Learn more: https://accessiblemeds.org/resources/blog/2025-savings-report

06/04/2026

PBMs were established to manage the high costs of prescription medicines, but their current opaque practices often serve to increase them – at the pharmacy counter and at the expense of taxpayers and patients.

Bottom Line: PBMs Prioritize Profits Over Affordability

Learn more: https://accessiblemeds.org/advocacy/pbm-reform/

06/01/2026

What’s next for generics & biosimilars? Hear it from the FDA at 2026. Join industry leaders in Rockville this November for key regulatory insights shaping the future. Register today and save! https://grxbiosims.org

05/28/2026

05/27/2026

DRUG SHORTAGES HAMPER PATIENT CARE! Continued drug shortages are a result of unsustainably low pricing, increases in government policies – including tariffs – that further compound market dynamics, and regulatory challenges. Learn more in the : https://accessiblemeds.org/resources/blog/2025-savings-report

05/22/2026

Sponsorship and exhibitor opportunities are now open for 2026! 🚀 As the leading regulatory, science, and policy event for the U.S. generics and biosimilars industry, GRx+Biosims is where innovation, insight, and industry leaders converge.

As an exhibitor, you’ll benefit from dedicated networking time with key decision-makers and peers, giving you the opportunity to:
✅ Build brand awareness
✅ Connect with new prospects
✅ Strengthen client relationships
✅ Leave with real, actionable leads

💡 Plus, gain direct access to U.S. regulatory experts and critical policy updates that matter—fueling your company’s growth and your own professional development.

Make your mark at GRx+Biosims 2026. Reserve your exhibit space today: https://grxbiosims.org/

05/19/2026

Right now, little is being done to infuse sustainability into the generic marketplace. Compared to 30 years ago, generic drugs are launching at lower prices and bottoming out at lower prices. This deflation puts savings and America’s patients in jeopardy. Learn what can be done to help safeguard the savings for patients AND help strengthen the industry: https://accessiblemeds.org/resources/blog/2025-savings-report

05/12/2026

Comprising only 1.2 percent of total U.S. healthcare spending in 2024, generic medicines saved American’s $467 billion—providing patients the health and financial outcomes necessary to thrive. https://accessiblemeds.org/resources/blog/2025-savingsreport

05/07/2026

brings together the leaders driving access and affordability in healthcare — and early registrants get the advantage.

Early Bird pricing is available for a limited time — giving you the best rate to attend the most important
conversations in the industry.

Why GRx+BIOSIMS?
Because this is where planning turns into action:
✅ Policy and regulatory concerns meet real-world impact
✅ Access challenges meet actionable solutions
✅ Industry leaders connect and collaborate
✅ You’ll leave with insights, connections, and strategies you can put to work immediately.

Plan Early. Save More. Lead the Conversation.
Early Bird rates won’t last so make your plans now.

Secure your spot & save: https://accessiblemeds.org/events/grxbiosims-2026/